118th Congress · HOUSE BILLBILL

H.R. 6227 — Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

“To amend the Federal Food, Drug, and Cosmetic Act to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.”

Health

Introduced Nov 3, 2023

Last action Nov 10, 2023

Pipeline · Bill → Law

Step 1

Introduced

Nov 3, 2023

Step 2

Referred

Nov 10, 2023

E&C

Step 3

Committee

Step 4

House floor

Step 5

Senate

Step 6

Resolve Changes

Step 7

Signed

SummaryCRS Summary

This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

Provisions · 2 sectionsIntroduced in House

Timeline · 3 actions

Nov 10, 2023

Referred to the Subcommittee on Health.

Nov 3, 2023

Introduced in House

Nov 3, 2023

Referred to the House Committee on Energy and Commerce.